Aurum Biosciences is pioneering innovative therapeutics and diagnostics aimed at addressing significant clinical needs, particularly in the treatment of Acute Ischemic Stroke (AIS) and Spinal Cord Injury (SCI). Their lead product, ABL-101, is an injectable therapy designed to deliver oxygen directly to tissues affected by these conditions, potentially bypassing blood clots that obstruct normal blood flow. This capability is crucial, as AIS is a leading cause of death and disability worldwide, and many patients are ineligible for existing treatments. ABL-101 not only aims to protect brain and spinal cord tissue from irreversible damage but also enhances the efficacy of current therapeutic options by working synergistically with existing treatments.

In addition to its therapeutic applications, Aurum is developing advanced imaging technologies to improve stroke diagnostics. Their proprietary Glasgow Oxygen Level Dependent (GOLD) imaging technique utilizes ABL-101 to identify salvageable brain tissue, offering a more precise assessment of metabolic integrity compared to traditional imaging methods. Furthermore, ABL-101's unique composition allows for visualization using fluorine-19 MRI, enabling the detection of inflammation in the brain and atherosclerotic plaques. This dual functionality positions Aurum's technology as a transformative approach in both the treatment and diagnosis of conditions related to compromised blood supply, with potential applications extending into inflammation, oncology, and cardiovascular diseases.

United Kingdom

Aurum Biosciences is developing novel therapeutics and diagnostics in areas of unmet clinical need. The initial indication for Aurum's ABL-101 injectable is for the treatment of acute ischemic stroke. The company is focused on developing oxygen carriers for use as therapeutics and diagnostics.

Aurum Biosciences

Company Details